Edwards Lifesciences price target lowered to $87 from $89 at Canaccord

Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences (EW) to $87 from $89 and keeps a Hold rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.